New Zealand markets close in 3 hours 4 minutes

Regulus Therapeutics Inc. (RGLS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.1400+0.0900 (+4.39%)
At close: 04:00PM EDT
2.1400 0.00 (0.00%)
After hours: 07:44PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 134.21M
Enterprise value 38.06M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.25
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.57

Trading information

Stock price history

Beta (5Y monthly) 1.64
52-week change 347.48%
S&P500 52-week change 324.96%
52-week high 33.7900
52-week low 31.0800
50-day moving average 32.2850
200-day moving average 31.7335

Share statistics

Avg vol (3-month) 3674.12k
Avg vol (10-day) 31.95M
Shares outstanding 565.47M
Implied shares outstanding 665.47M
Float 842.96M
% held by insiders 11.68%
% held by institutions 190.81%
Shares short (15 May 2024) 42.88M
Short ratio (15 May 2024) 47.15
Short % of float (15 May 2024) 45.60%
Short % of shares outstanding (15 May 2024) 44.40%
Shares short (prior month 15 Apr 2024) 46.27M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 304 Oct 2018
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 329 Jun 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-26.93%
Return on equity (ttm)-46.75%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -32.31M
Net income avi to common (ttm)-31.37M
Diluted EPS (ttm)-1.4500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)97.55M
Total cash per share (mrq)1.49
Total debt (mrq)2.14M
Total debt/equity (mrq)1.99%
Current ratio (mrq)17.85
Book value per share (mrq)1.64

Cash flow statement

Operating cash flow (ttm)-27.4M
Levered free cash flow (ttm)-17.54M